Spots Global Cancer Trial Database for DCF Combined With Camrelizumab in the Treatment of Esophageal Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: DCF Combined With Camrelizumab in the Treatment of Esophageal Cancer
Official Title: An Exploratory Study of the Efficacy and Safety of DCF Regimen Combined With Camrelizumab in the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma(ESCC)
Study ID: NCT05050760
Conditions
Study Description
Brief Summary: To evaluate the safety and feasibility of DCF combined with camrelizumab in the treatment of locally advanced ESCC
Detailed Description: Primary outcome: To evaluate the safety and feasibility of DCF combined with camrelizumab in the treatment of locally advanced ESCC Secondary outcome: pathologic complete response (pCR)、Major Pathologic Response（MPR）、R0 resection rate、Objective response rate（ORR）、Disease free survival（DFS）、Relief rate and safety of dysphagia
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Xijing Hospital, Xi'an, Shaanxi, China
Contact Details
Name: Jianjun Yang
Affiliation: Xijing Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
